Health · Neuroscience

A Common Constipation Drug Just Cleared Depression Brain Fog in a Clinical Trial

Prucalopride, a medication already approved for chronic constipation, improved memory, attention, and processing speed in people who had recovered from depression — pointing to a surprising new treatment for cognitive symptoms that affect 80% of patients.

Depression does not just steal motivation and mood — it clouds the mind. Up to 80% of people with depression report "brain fog": difficulty concentrating, slower thinking, and trouble remembering. Now researchers at the University of Birmingham have found an unlikely candidate that may help.

In a double-blind, placebo-controlled trial, 50 adults with a history of major depressive episodes were given either 2 mg of prucalopride or a placebo for seven to ten days. Prucalopride is a 5-HT4 receptor agonist — a drug that activates a serotonin receptor found both in the gut and the brain. It is currently prescribed for chronic constipation.

What the trial found

How does a constipation drug affect the brain?

The 5-HT4 receptor is abundant in the hippocampus and prefrontal cortex — brain regions critical for memory and executive function. By activating these receptors, prucalopride may boost the release of acetylcholine and other neurotransmitters essential for cognitive processing. The gut-brain connection is not just a metaphor: the same serotonin receptor that regulates intestinal movement also modulates learning and memory.

Why it matters

Cognitive symptoms of depression are among the most disabling and hardest to treat. Standard antidepressants like SSRIs often improve mood but do little for brain fog, and some even worsen cognitive function. Prucalopride is already licensed, inexpensive, and well-tolerated — meaning it could be rapidly repurposed if larger trials confirm the results. The University of Birmingham team is now planning a larger, longer study to test whether the benefits persist and whether the drug works in people currently experiencing a depressive episode, not just those in recovery.

If confirmed, prucalopride would be one of the first medications specifically targeting the cognitive dimension of depression — a breakthrough for millions who struggle to think clearly, even when their mood stabilizes.